MedPath

GI Innovation, Inc.

GI Innovation, Inc. logo
🇰🇷South Korea
Ownership
Public
Established
2017-01-01
Employees
101
Market Cap
-
Website
http://www.gi-innovation.com

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Metastatic Solid Tumor
Soft Tissue Sarcoma (STS)
Platinum-resistant Ovarian Cancer (PROC)
Hepatocellular Carcinoma (HCC)
Colorectal Cancer (CRC)
HER2 Negative Breast Cancer
Cutaneous Melanoma
Renal Cell Carcinoma (RCC)
Interventions
First Posted Date
2023-04-24
Last Posted Date
2024-11-25
Lead Sponsor
GI Innovation, Inc.
Target Recruit Count
358
Registration Number
NCT05824975
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Minnesota, Rochester, Minnesota, United States

and more 7 locations

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Cervical Cancer
Vaginal Cancer
Renal Cell Carcinoma
Melanoma
Sarcoma
Microsatellite Stable Colorectal Carcinoma
Esophageal Squamous Cell Carcinoma
Vulvar Cancer
Advanced Solid Tumor
Non-small Cell Lung Cancer
Interventions
Drug: Pembrolizumab (KEYTRUDA®)
Drug: GI-101
Radiation: Local Radiotherapy
Drug: GI-101A
Drug: Lenvatinib
First Posted Date
2021-07-27
Last Posted Date
2024-02-22
Lead Sponsor
GI Innovation, Inc.
Target Recruit Count
430
Registration Number
NCT04977453
Locations
🇺🇸

Tisch Cancer Institute (TCI), Icahn School of Medicine, New York, New York, United States

🇺🇸

Carolina Biooncology Institute, Huntersville, North Carolina, United States

🇰🇷

The Catholic University of Korea St. Vincent's Hospital, Suwon-si, Kyeonggi-do, Korea, Republic of

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath